Novel multi target-directed ligands targeting 5-HT


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Nov 2019
Historique:
received: 31 05 2019
revised: 19 07 2019
accepted: 05 08 2019
pubmed: 17 8 2019
medline: 22 11 2019
entrez: 17 8 2019
Statut: ppublish

Résumé

Facing the complexity of Alzheimer's disease (AD), it is now currently admitted that a therapeutic pleiotropic intervention is needed to alter its progression. Among the major hallmarks of the disease, the amyloid pathology and the oxidative stress are closely related. We propose in this study to develop original Multi-Target Directed Ligands (MTDL) able to impact at the same time Aβ protein accumulation and toxicity of Reactive Oxygen Species (ROS) in neuronal cells. Such MTDL were obtained by linking on a central piperidine two scaffolds of interest: a typical aminochlorobenzophenone present in numerous 5-HT

Identifiants

pubmed: 31419776
pii: S0223-5234(19)30730-5
doi: 10.1016/j.ejmech.2019.111596
pii:
doi:

Substances chimiques

Antioxidants 0
Biphenyl Compounds 0
Ligands 0
Picrates 0
Reactive Oxygen Species 0
Serotonin 5-HT4 Receptor Agonists 0
Receptors, Serotonin, 5-HT4 158165-40-3
1,1-diphenyl-2-picrylhydrazyl DFD3H4VGDH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111596

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Caroline Lanthier (C)

Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Hugo Payan (H)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.

Irene Liparulo (I)

Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, I-40126, Bologna, Italy.

Bérénice Hatat (B)

Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie Univ, UNICAEN, CERMN, 14000, Caen, France; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.

Cédric Lecoutey (C)

Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Marc Since (M)

Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Audrey Davis (A)

Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Christian Bergamini (C)

Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, I-40126, Bologna, Italy.

Sylvie Claeysen (S)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.

Patrick Dallemagne (P)

Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Maria-Laura Bolognesi (ML)

Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, I-40126, Bologna, Italy.

Christophe Rochais (C)

Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie Univ, UNICAEN, CERMN, 14000, Caen, France. Electronic address: christophe.rochais@unicaen.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH